Results 181 to 190 of about 122,145 (339)

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Novel Compounds as Glucagon-Like Peptide‑1 Receptor Agonists for Treating Diabetes. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptors agonists (GLP1 RA).

JPMA. The Journal of the Pakistan Medical Association, 2014
The glucagon-like peptide-1 receptors agonists (GLP1RA) are a relatively new class of drugs, used for management of type 2 diabetes. This review studies the characteristics of these drugs, focusing upon their mechanism of action, intra-class differences, and utility in clinical practice.
openaire   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Complete Skin Remission of Lichen Planus With Tirzepatide

Australasian Journal of Dermatology, EarlyView.
Harmeet Bhullar, Emma Veysey, Tanya Bohl, Saurabh Prakash, Sarah Smithson   +4 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source